Log in to search using one of your social media accounts:

 

Sofosbuvir Safe, Effective for HCV in Those With CKD Sofosbuvir Safe, Effective for HCV in Those With CKD
Sofosbuvir-based antiviral therapy cured hepatitis C virus infection in more than 80% of patients with chronic kidney disease, a retrospective cohort study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Treating a little-known virus, CMV, to combat hearing loss in children
(University of Utah Health) A National Institutes of Health-supported nationwide clinical trial will test a novel approach to combat hearing loss in children infected by a relatively unknown virus, cytomegalovirus (CMV). The University of Utah Health-led study will determine whether antiviral therapy can halt progressive hearing loss in children with a confirmed CMV infection. CMV is the leading non-genetic cause of hearing loss, contributing from 6 to 30 percent of childhood cases. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2017 Category: Infectious Diseases Source Type: news

Antiviral Therapy in Patients With Influenza Antiviral Therapy in Patients With Influenza
Which patients should receive antiviral therapy for influenza, and what are the currently available options?U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Subcirrhotic Liver Stiffness Cuts HCC Risk in Hepatitis B
Achievement of subcirrhotic range of liver stiffness with antiviral therapy reduces HCC risk (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 10, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Infections, Internal Medicine, Oncology, Journal, Source Type: news

Antiviral therapy is effective in fighting hepatitis C | Letters
The Cochrane analysis casting doubt on this life-saving therapy is flawed and may deter patients from seeking it, say clinicians and scientistsWe are clinicians and scientists who have studied and treated patients with chronic hepatitis C virus infection over many years and patient groups that represent those affected by hepatitis C. We write in response to your article on the effectiveness of antiviral therapy (Hepatitis ‘wonder drug’ may be clinically ineffective, say experts, 9 June). The Cochrane review that you highlight analysed clinical trials, which are by nature short term, where the sole purpose was t...
Source: Guardian Unlimited Science - June 13, 2017 Category: Science Authors: Letters Tags: Hepatitis C Health Pharmaceuticals industry Medical research Drugs Business Science UK news Society Source Type: news

The Potential Role of Polymerase Chain Reaction in Diagnosis of Neonatal Herpes Simplex Virus Infection: Is Viral Culture Outdated?
Even in the era of effective antiviral therapy, neonatal herpes simplex viral infection causes significant morbidity and mortality in newborns. Prompt diagnosis is the cornerstone of treatment of these infants. Outside and inside the neonatal clinical practice, polymerase chain reaction (PCR) is replacing culture as a method of facilitating a speedy diagnosis of herpes simplex virus infection. New pediatric guidelines call for testing of high-risk asymptomatic infants, and thus, many more surface cultures and PCRs are being performed. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - June 6, 2017 Category: Microbiology Authors: Nicole L. Samies, Swathi M. Gowtham Source Type: news

IRE1{alpha} promotes viral infection by conferring resistance to apoptosis
The unfolded protein response (UPR) is an ancient cellular pathway that detects and alleviates protein-folding stresses. The UPR components X-box binding protein 1 (XBP1) and inositol-requiring enzyme 1α (IRE1α) promote type I interferon (IFN) responses. We found that Xbp1-deficient mouse embryonic fibroblasts and macrophages had impaired antiviral resistance. However, this was not because of a defect in type I IFN responses but rather an inability of Xbp1-deficient cells to undergo viral-induced apoptosis. The ability to undergo apoptosis limited infection in wild-type cells. Xbp1-deficient cells were generall...
Source: Signal Transduction Knowledge Environment - June 6, 2017 Category: Science Authors: Fink, S. L., Jayewickreme, T. R., Molony, R. D., Iwawaki, T., Landis, C. S., Lindenbach, B. D., Iwasaki, A. Tags: STKE Research Articles Source Type: news

Risk of HBV Reactivation in Patients on Antivirals for HCV Risk of HBV Reactivation in Patients on Antivirals for HCV
Is there a clinically relevant risk of HBV reactivation during direct-acting antiviral therapy for HCV with an interferon-free regimen?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant HBIG Plus Antivirals May Prevent HBV Reinfection After Transplant
A very short course of hepatitis B immunoglobulin (HBIG) after liver transplantation, along with long-term antiviral therapy, may prevent hepatitis B virus (HBV) reinfection, a retrospective study suggests.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 22, 2017 Category: Transplant Surgery Tags: Transplantation News Source Type: news

Prevalence and Impact of Steatohepatitis in HBV Patients Prevalence and Impact of Steatohepatitis in HBV Patients
This study assessed the prevalence of steatohepatitis in chronic HBV-infected patients, its risk factors, and its correlation with liver fibrosis and response to antiviral therapy.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Dateline City: KENILWORTH, N.J. Findings Presented at The International Liver Congress ™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) fromC-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2/grazoprevir3...
Source: Merck.com - Research and Development News - April 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hepatitis C MSD NYSE:MRK Source Type: news

Hepatitis C treatment can be provided successfully at syringe programme sites
Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City. (Source: PHPartners.org)
Source: PHPartners.org - April 19, 2017 Category: Global & Universal Source Type: news

Poor Adherence to Antiviral Treatment for Hepatitis B Poor Adherence to Antiviral Treatment for Hepatitis B
Antiviral therapy for hepatitis B is effective and improves outcomes, but is often long-term, and adherence can be poor. What factors might influence non-adherence to therapy?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 9, 2017 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Scientists crack the structure of HIV machinery
Antiviral therapy could be improved with newly uncovered atomic-level details of the structure of HIV machinery, report researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 5, 2017 Category: Science Source Type: news

Salk scientists crack the structure of HIV machinery
(Salk Institute) Antiviral therapy could be improved with the newly uncovered atomic-level details. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 5, 2017 Category: Biology Source Type: news

Novel Treatment Could Lead to Functional Control of Hep B Novel Treatment Could Lead to Functional Control of Hep B
Nucleic acid polymers block the release of the hepatitis B surface antigen from hepatocytes, boosting the efficacy of standard antiviral therapy, according to an early clinical trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 17, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Costs of HCV greater without antiviral therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Comparative Effectiveness of HCV Combination Therapies Comparative Effectiveness of HCV Combination Therapies
This analysis compared the efficacy of two commonly used regimens of oral antiviral therapy in a cohort of veterans with hepatitis C.Alimentary Pharmacology & Therapeutics (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 9, 2016 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Big step towards cure for HIV and other lifelong viral infections
New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such as HIV, cannot be cured with antiviral therapy because the virus effectively hides from the immune system. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 4, 2016 Category: Science Source Type: news

Big step towards cure for lifelong viral infections
(Monash University) New research has taken us a step closer to finding a cure for human immunodeficiency virus (HIV), as well as other infections including the glandular fever virus, which is associated with the development of lymphoma. Some infections, such as HIV, cannot be cured with antiviral therapy because the virus effectively hides from the immune system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 3, 2016 Category: Global & Universal Source Type: news

Direct Acting Antiviral Therapy After Liver TransplantationDirect Acting Antiviral Therapy After Liver Transplantation
Which direct acting antiviral agents are most effective for patients, and do they help contribute to long-term survival? Current Opinion in Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2016 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer Found in Hepatitis C Patients on New AntiviralsLiver Cancer Found in Hepatitis C Patients on New Antivirals
For patients infected with chronic hepatitis C virus, there could be a downside to direct-acting antiviral therapy, which has been hailed as a cure. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

First Evidence That Hep C Drugs Curb Liver TransplantsFirst Evidence That Hep C Drugs Curb Liver Transplants
Patients are being delisted from liver transplant wait lists because of direct-acting antiviral therapy, investigators report, but there are no long-term data to predict their future, experts caution. Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 15, 2016 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news

Antiviral therapy prolongs survival in immune tolerant hepatitis B patients
A new study demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 15, 2016 Category: Science Source Type: news

Antiviral therapy prolongs survival in immune tolerant hepatitis B patients
(European Association for the Study of the Liver) A new study, presented today at The International Liver Congress™ 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 15, 2016 Category: Infectious Diseases Source Type: news

Treating patients for hepatitis C could reduce the need for liver transplants
(European Association for the Study of the Liver) A new study presented today demonstrates that patients on the liver transplant list with hepatitis C virus (HCV) and severe liver damage were more likely to be taken off the list or have their need of a liver transplant reduced as a result of direct-acting antiviral therapy. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2016 Category: Infectious Diseases Source Type: news

Suspected Flu in a High-risk Patient? Don't Delay Antiviral Therapy
The CDC is urging physicians to be more proactive in prescribing antiviral medications for severely ill or high-risk patients in whom flu is suspected or confirmed. (Source: AAFP News)
Source: AAFP News - February 5, 2016 Category: Primary Care Source Type: news

Antiviral Therapy in Chronic Hepatitis EAntiviral Therapy in Chronic Hepatitis E
Does the latest research recommend ribavirin monotherapy as an effective and relatively safe treatment for patients with chronic hepatitis E? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Sofosbuvir and Simeprevir in Liver Transplant RecipientsSofosbuvir and Simeprevir in Liver Transplant Recipients
How safe and effective is combination antiviral therapy in the treatment of recurrent hepatitis C in liver transplant patients? Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 25, 2015 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

FDA-approved drug protects mice from Ebola
(University of Iowa Health Care) A new study suggests that gamma interferon, which is an FDA-approved drug, may have potential as an antiviral therapy to prevent Ebola infection when given either before or after exposure to the virus. The University of Iowa study, published Nov. 12 in the journal PLOS Pathogens, found that gamma interferon, given up to 24 hours after exposure, can inhibit Ebola infection in mice and completely protect the animals from death. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 18, 2015 Category: Infectious Diseases Source Type: news

Mechanisms of Non-response to Hepatitis C TherapyMechanisms of Non-response to Hepatitis C Therapy
How does cirrhosis affect the response to antiviral therapy in patients with hepatitis C? Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

All-oral, DAA options for HCV effective & well tolerated in patients with decompensated cirrhosis
(European Association for the Study of the Liver) Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response at four weeks was shown to be: sofosbuvir/ribavirin: 75 percent; sofosbuvir/simeprevir: 77 percent; sofosbuvir/simeprevir/ribavirin: 81 percent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2015 Category: Biology Source Type: news

Perinatal HBV: Timely Immunoprophylaxis Effective Perinatal HBV: Timely Immunoprophylaxis Effective
Maternal antiviral therapy may be the next step for further decreasing perinatal HBV infections. Medscape Medical News (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - April 21, 2015 Category: OBGYN Tags: Pediatrics News Source Type: news

Researchers Explore Hepatitis B Reactivation in Patients With Rheumatoid Arthritis Treated With Both DMARD and Antiviral Therapy
Source: Lippincott’s Bone and Joint Newsletter - March 20, 2015 Category: Orthopaedics Tags: CME Article Source Type: news

NIH-led study to assess community-based hepatitis C treatment in Washington, D.C.
(NIH/National Institute of Allergy and Infectious Diseases) Officials from NIH and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. The trial, which will involve 600 adult D.C. residents infected with HCV alone or co-infected with HCV and HIV, also will examine the long-term effects of the treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2015 Category: Global & Universal Source Type: news

Cirrhosis Regression in HCV Patients After Antiviral TherapyCirrhosis Regression in HCV Patients After Antiviral Therapy
Do the majority of patients with cirrhosis who achieve a sustained virological response develop cirrhosis regression? This new study investigates. Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Identification of Protein Receptors for Coronaviruses by Mass Spectrometry
As obligate intracellular parasites, viruses need to cross the plasma membrane and deliver their genome inside the cell. This step is initiated by the recognition of receptors present on the host cell surface. Receptors can be major determinants of tropism, host range, and pathogenesis. Identifying virus receptors can give clues to these aspects and can lead to the design of intervention strategies. Interfering with receptor recognition is an attractive antiviral therapy, since it occurs before the viral genome has reached the relative safe haven within the cell. This chapter describes the use of an immunoprecipitation app...
Source: Springer protocols feed by Microbiology - February 28, 2015 Category: Microbiology Source Type: news

Protecting Children: Influenza Updates for Clinicians
February 26, 2015, 2:00-3:00 PM EST. During this webinar, clinicians will learn about the current state of flu activity related to children, the importance of continued vaccination despite the mismatch and low vaccine effectiveness, and strategies for using antiviral therapy early to prevent and treat influenza. (Source: PHPartners.org)
Source: PHPartners.org - February 18, 2015 Category: Global & Universal Source Type: news

5-Year-Old Boy In NYC Tests Negative For Ebola
(Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - October 27, 2014 Category: Consumer Health News Source Type: news

Varicella-Zoster Virus Infection in Children and AdolescentsVaricella-Zoster Virus Infection in Children and Adolescents
Which children should receive antiviral therapy for chickenpox? U.S. Pharmacist (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 23, 2014 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

J&J's Hera Therapeutics Presents Antiviral Drug For HPV
Scientists from Hera Therapeutics, part of the Janssen Labs under the Johnson & Johnson’s external R&D engine, presented results suggesting that its small molecule HTI-1968 has potential as a direct-acting antiviral therapy against Human Papilloma Virus (HPV). (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - August 27, 2014 Category: Pharmaceuticals Source Type: news

Relapse Rates in Chronic HBV After Stopping AntiviralsRelapse Rates in Chronic HBV After Stopping Antivirals
How can clinicians prevent relapse in patients with chronic hepatitis B after discontinuation with antiviral therapy? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2014 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Influenza: Complications in 1 in 3 Previously Healthy Kids Influenza: Complications in 1 in 3 Previously Healthy Kids
As many as 1 in 3 children seeking treatment for influenza-like illnesses at the peak of influenza season are at high risk of suffering severe complications, arguing for antiviral therapy scripts. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 4, 2014 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Should donor blood be screened for hepatitis E?
Conclusion This study estimated the prevalence of hepatitis E virus in blood donors and found a higher than expected figure of around one infection in every 2,848 donors. They found the infection was passed to the recipient of the blood in some cases, but this did not cause significant illness and recipients were able to clear the virus from their bodies naturally in most cases. This study, which coincides with World Hepatitis Day, increases our awareness that the prevalence of hepatitis E in England might be higher than previously assumed. A second issue stemming from the study is whether, given the higher than expected...
Source: NHS News Feed - July 28, 2014 Category: Consumer Health News Tags: Medical practice Source Type: news

Drug that reduces abdominal fat in HIV patients also may reduce fat in liver
(Massachusetts General Hospital) The only drug to receive Food and Drug Administration approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. Massachusetts General Hospital investigators report that six months of daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 19, 2014 Category: Global & Universal Source Type: news

Findings suggest antivirals underprescribed for patients at risk for flu complications
(Infectious Diseases Society of America) Patients likely to benefit the most from antiviral therapy for influenza were prescribed these drugs infrequently during the 2012-2013 influenza season, while antibiotics may have been overprescribed. Published in Clinical Infectious Diseases and now available online, the findings suggest more efforts are needed to educate clinicians about the appropriate use of antivirals and antibiotics in the outpatient setting. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 17, 2014 Category: Infectious Diseases Source Type: news

Predicting the outcome of hepatitis C virus treatment
(Journal of Clinical Investigation) A study published in the Journal of Clinical Investigation identifies a marker that can identify patients likely to have an HCV relapse after antiviral therapy. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 1, 2014 Category: Infectious Diseases Source Type: news

Antiviral therapy can prevent liver cancer in chronic hepatitis B patients
(American Gastroenterological Association) One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. Two new studies appearing in the June issue of Gastroenterology provide strong evidence that antiviral therapy can reduce the risk of liver cancer in patients with chronic hepatitis B infection. Gastroenterology is the official journal of the American Gastroenterological Association. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 23, 2014 Category: Infectious Diseases Source Type: news

Antiviral therapy may prevent liver cancer in hepatitis B patients
(Henry Ford Health System) Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma. 'The results of this study allow us to reassure our patients that we are not just treating their viral levels, but that antiviral therapy may actually lessen their chance of developing liver cancer,' said the study's lead investigator, Henry Ford Health System's Stuart C. Gordon, M.D. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 9, 2014 Category: Global & Universal Source Type: news

USPSTF Recommends Hepatitis B Screening for High-Risk Groups (FREE)
By Amy Orciari Herman The U.S. Preventive Services Task Force now recommends screening for hepatitis B virus (HBV) infection in high-risk groups, given the accuracy of serologic testing and the effectiveness of antiviral therapy.High-risk groups include: people born in … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 27, 2014 Category: Primary Care Source Type: news